Celltrion
Celltrion Healthcare Co., Ltd., commonly known as Celltrion, is a leading biopharmaceutical company headquartered in South Korea (KR). Founded in 2002, Celltrion has established itself as a key player in the global biotechnology industry, focusing on the development, manufacturing, and marketing of biosimilars and innovative therapeutics. With a strong presence in major operational regions including Europe, the Americas, and Asia, Celltrion is renowned for its core products, such as Remsima and Truxima, which are biosimilars to established monoclonal antibodies. These products are distinguished by their high quality and affordability, making advanced treatments accessible to a broader patient population. Celltrion's commitment to research and development has led to significant milestones, including the successful launch of multiple biosimilars that have garnered regulatory approvals worldwide. As a pioneer in the biosimilar market, Celltrion continues to enhance its market position through innovation and strategic partnerships, contributing to the evolution of healthcare solutions globally.
DitchCarbon Score
How does Celltrion's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Celltrion's score of 68 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Celltrion's reported carbon emissions
In 2024, Celltrion reported total greenhouse gas (GHG) emissions of approximately 13,279,700 kg CO2e globally, with emissions distributed across Scope 1 (661,710 kg CO2e), Scope 2 (25,900 kg CO2e), and a significant portion from Scope 3 emissions. The company has set ambitious climate commitments, aiming to reduce GHG emissions by 50% by 2030 compared to 2020 levels. Additionally, Celltrion is working towards achieving carbon neutrality by 2050. For its domestic operations, Celltrion has committed to mitigating Scope 1 and 2 emissions by 42% by 2030 and achieving a 100% reduction by 2045, using 2022 as the baseline year. Specifically, Celltrion Healthcare UK aims to reduce Scope 1 and Scope 2 emissions by 42% from 2022 levels by 2030. The emissions data for 2023 indicates a total of approximately 28,798,000 kg CO2e, with Scope 1 emissions at 22,457,000 kg CO2e and Scope 2 at 42,260,000 kg CO2e. The company has shown a commitment to transparency and accountability in its sustainability efforts, as evidenced by its detailed reporting and reduction targets.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 16,864,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000 |
| Scope 2 | 31,667,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000 |
| Scope 3 | - | - | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Celltrion is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
